On the 8th, L&K BIOMED CO., LTD. announced that, as of last month, Pectus had surpassed 1 billion won (approximately $700,000) in monthly sales as a single product. This achievement represents a figure equivalent to the company’s quarterly sales from last year, accomplished in just one month. It also marks the company’s highest-ever monthly sales figure.
This sales increase is attributed to the expanded use of Pectus within major U.S. hospital networks. As the number of surgical cases has risen at medical institutions with high surgical volumes, this has led to increased sales. In particular, the company views securing a reference at Phoenix Children’s Hospital as a key growth factor.
Phoenix Children’s Hospital is a leading U.S. institution for the treatment and education of chest wall deformities. It serves as a training center that offers basic and advanced training courses annually to medical professionals specializing in chest wall deformities across the United States, and it is also driving the adoption of the latest surgical techniques.
L&K BIOMED CO., LTD. attaches significant importance to the fact that Factus was adopted by Phoenix Children’s Hospital, where products from a specific global company had long been used as the de facto standard. The company explains that this serves as an example demonstrating the potential for change in the existing market landscape.
Dr. McMahon, a leading authority on chest wall deformities at Phoenix Children’s Hospital and a key scholar at the Global Chest Wall Institute (CWIG), personally performed surgery using Factus and gave a positive evaluation of the product in terms of ease of use and patient recovery.
Factus is an integrated system that holds proprietary design technologies and patents across all major components used in chest wall deformity correction surgery, including the bar, connector, and fixation device.
In particular, the company has built a patent portfolio covering core technologies such as a structure that allows for mid-bar insertion, connectors that enable positional adjustment and stable fixation, and internal, embedded fixation devices within the bar that minimize skin protrusion and the sensation of a foreign body.
An L&K BIOMED CO., LTD. official stated, “Surpassing 1 billion won in monthly sales is more than just an improvement in performance; it is an important milestone demonstrating that our proprietary patented technology is being progressively validated in the global medical market,” adding, “As clinical applications are rapidly expanding at major U.S. medical institutions, starting with world-class reference centers, we plan to focus our efforts on establishing Factus as the new global standard for the treatment of chest wall deformities.”
Meanwhile, L&K BIOMED CO., LTD. is currently proceeding with discussions regarding collaborations and agreements with major global companies.
